The Essential Medicines Gap: Why Pharmacogenomics is a Missing Piece for Safer Women’s Health
A new analysis of the World Health Organization’s Essential Medicines List reveals a critical oversight: pharmacogenomic guidance is absent, potentially compromising treatment safety and efficacy. The study systematically reviewed the 2023 WHO list and 52 national lists from African countries, finding that an average of one in eight essential medicines has established, actionable pharmacogenomic biomarkers.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
